Compare TG Therapeutics Inc (TGTX) vs Upstart Holdings Inc (UPST) Price & Performance

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.

Upstart Holdings (UPST) trades at $24.10, showing modest daily gains but facing technical bearish signals. The company achieved profitability in 2025 with $1.02B revenue and $53.6M net income, though recent quarters show earnings misses. Analyst sentiment is mixed with a $39.50 price target, while technical indicators suggest near-term resistance at $25. Recent news highlights partnership expansions and securitization activity amid sector-wide pressure on consumer lending stocks.

UPST presents a turnaround story with improving fundamentals but faces execution risks in a challenging lending environment. The stock trades below analyst targets offering potential upside, though volatility remains high given recent earnings misses and competitive pressures. Key catalysts include AI lending platform adoption and credit market stability, while risks involve credit quality deterioration and macroeconomic headwinds affecting loan demand.